ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Boston, MA, USA:

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Worcester, Massachusetts, United States and 18 other locations

will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

Phase 1

Roche
Roche

Worcester, Massachusetts, United States and 20 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Boston, Massachusetts, United States and 107 other locations

of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).The primary objectives that this stu...

Enrolling
Secondary Progressive Multiple Sclerosis
Drug: Foralumab
Other: Placebo

Phase 2

Tiziana Life Sciences

Boston, Massachusetts, United States

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple...

Enrolling
Multiple Sclerosis
Clinically Isolated Syndrome
Drug: Ocrelizumab

Phase 4

Roche
Roche

Boston, Massachusetts, United States and 9 other locations

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Worcester, Massachusetts, United States and 23 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Boston, Massachusetts, United States and 121 other locations

Locations recently updated

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Worcester, Massachusetts, United States and 36 other locations

Locations recently updated

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Worcester, Massachusetts, United States and 35 other locations

A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Boston, Massachusetts, United States and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems